April 29, 2020
Hydroxychloroquine (HCQ) has received U.S. Food and Drug Administration (FDA) emergency use authorization for coronavirus disease, but so far there is no scientific proof it helps those afflicted Novartis has reached an agreement with U.S. regulators to hold a randomized trial of generic malaria drug hydroxychloroquine against COVID-19 disease in 440 hospitalised patients, the Swiss drugmaker said on Monday. The decades-old medicine has received U.S. Food and Drug Administration (FDA) emergency use authorization for coronavirus disease, but so far there is no scientific proof it helps those afflicted.
“We recognize the importance of answering the scientific question of whether hydroxychloroquine will be beneficial for patients with COVID-19 disease,” said John Tsai, Novartis’s top drug developer. The drug also used to treat lupus and rheumatoid arthritis, has been promoted by President Donald Trump, with some worried the administration’s advocacy for an unproven medicine for COVID-19 has short-circuited the oversight process.
For more details contact us.
Health Sansar provides a wealth of trending topics that allow individuals to stay updated and informed about the latest developments in the health and wellness domain. Health Sansar offers a comprehensive platform for users to access current and relevant information in the ever-evolving field of health.